Amexdrug Corporation
Amexdrug Corporation, a pharmaceutical and cosmeceutical company, through its subsidiaries, primarily distributes pharmaceutical products. It is also involved in the research, development, manufacture, and sale of pharmaceutical drugs, cosmetics, and medical devices. The company operates in two segments, Distribution and Health and Beauty Products. In addition, it engages in the distribution of p… Read more
Amexdrug Corporation (AXRX) - Total Assets
Latest total assets as of June 2025: $2.42 Million USD
Based on the latest financial reports, Amexdrug Corporation (AXRX) holds total assets worth $2.42 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Amexdrug Corporation - Total Assets Trend (2001–2024)
This chart illustrates how Amexdrug Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Amexdrug Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Amexdrug Corporation's total assets of $2.42 Million consist of 99.8% current assets and 0.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.0% |
| Accounts Receivable | $156.84K | 6.3% |
| Inventory | $576.35K | 23.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $-18.26K | -0.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2024)
This chart illustrates how Amexdrug Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amexdrug Corporation's current assets represent 99.8% of total assets in 2024, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 3.0% of total assets in 2024, down from 30.8% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
- Asset Diversification: The largest asset category is inventory at 23.2% of total assets.
Amexdrug Corporation Competitors by Total Assets
Key competitors of Amexdrug Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Amexdrug Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Amexdrug Corporation generates 1.37x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Amexdrug Corporation generates $ 0.46 in net profit.
Amexdrug Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.90 | 11.78 | 1.79 |
| Quick Ratio | 8.24 | 9.75 | 0.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.17 Million | $ 2.19 Million | $ 1.12 Million |
Amexdrug Corporation - Advanced Valuation Insights
This section examines the relationship between Amexdrug Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 51.38 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 1.0% |
| Total Assets | $2.49 Million |
| Market Capitalization | $19.17 USD |
Valuation Analysis
Below Book Valuation: The market values Amexdrug Corporation's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Amexdrug Corporation's assets grew by 1.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Amexdrug Corporation (2001–2024)
The table below shows the annual total assets of Amexdrug Corporation from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.49 Million | +1.04% |
| 2023-12-31 | $2.46 Million | -14.51% |
| 2021-12-31 | $2.88 Million | -22.23% |
| 2020-12-31 | $3.70 Million | +49.61% |
| 2019-12-31 | $2.47 Million | -9.52% |
| 2018-12-31 | $2.73 Million | +18.07% |
| 2017-12-31 | $2.31 Million | -0.52% |
| 2016-12-31 | $2.33 Million | +29.08% |
| 2015-12-31 | $1.80 Million | +29.54% |
| 2014-12-31 | $1.39 Million | -42.20% |
| 2012-12-31 | $2.41 Million | +50.61% |
| 2011-12-31 | $1.60 Million | +19.15% |
| 2010-12-31 | $1.34 Million | +68.03% |
| 2009-12-31 | $798.41K | +12.61% |
| 2008-12-31 | $709.00K | +2.01% |
| 2007-12-31 | $695.00K | +40.69% |
| 2006-12-31 | $494.00K | +6.93% |
| 2005-12-31 | $462.00K | +10.00% |
| 2004-12-31 | $420.00K | -31.37% |
| 2003-12-31 | $612.00K | -58.95% |
| 2002-12-31 | $1.49 Million | -18.30% |
| 2001-12-31 | $1.82 Million | -- |